Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
Authors:
Open Access
- 29 July 2023
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 62, 102109
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Biomedical Advanced Research and Development Authority
This publication has 20 references indexed in Scilit:
- Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022MMWR. Morbidity and Mortality Weekly Report, 2022
- Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studyThe Lancet Infectious Diseases, 2022
- Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in EnglandNature Medicine, 2022
- Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primatesScience, 2021
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysisNature Medicine, 2021
- Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging studyThe Lancet Infectious Diseases, 2021
- Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- CDC COVID-19 Science Briefs2020
- Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccinesVaccine, 2013
- A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2000